" class="no-js "lang="en-US"> Helena Chaye - Medtech Alert
Friday, April 19, 2024
Helena Chaye

Helena Chaye

About Helena Chaye

Helena has over 23 years of experience in the biotechnology industry having held leadership positions in operations, corporate affairs, business development and IP management primarily in oncolytic virotherapy development. Most recently, Helena served as Chief Business Officer at SillaJen Biotherapeutics, Inc. where she managed all operations including corporate and business development strategies, R&D strategy and intellectual property. Prior to joining SillaJen, Helena held the positions of VP of Corporate Affairs & IP at Jennerex Biotherapeutics and the Director of Business Development at MediGene. Helena received her B.S. in Biochemistry and her Ph.D. in Genetics from the University of British Columbia and her J.D. from Dalhousie University.

Related Story

ABL Partners With KaliVir Immunotherapeutics to Advance Development of Oncolytic Viruses

July 12 2022

ABL, a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and […]

KaliVir Immunotherapeutics Enters into Global Exclusive Licensing Agreement with Roche for Novel Oncolytic Viruses

May 24 2022

KaliVir Immunotherapeutics, Inc. today announced a collaboration and global exclusive licensing agreement with Roche for […]